37th week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170258701 | CLEANSING COMPOSITION - An aqueous cleansing composition comprises at least one amino acid surfactant, an aqueous non-ionic emulsion of divinyldimethicone/dimethicone copolymer, and at least one additional anionic surfactant, other than the at least one amino acid surfactant, wherein the at least one amino acid surfactant comprises at least one glutamate surfactant according to the general formula | 2017-09-14 |
20170258702 | BI-MODAL EMULSIONS - The present invention provides a process for making a bi-modal water continuous emulsion comprising forming a mixture comprising 100 parts by weight of a hydrophobic oil and 1 to 1000 part by weight of a water continuous emulsion having at least one surfactant, and admixing additional quantities of the water continuous emulsion and/or water to the mixture to form a bi-modal water continuous emulsion, wherein the water continuous emulsion forms a first dispersed phase of particle size P | 2017-09-14 |
20170258703 | IONIC/IONOGENIC COMB COPOLYMER COMPOSITIONS AND PERSONAL CARE PRODUCTS CONTAINING THE SAME - Ionic and ionogenic comb copolymers are disclosed along with personal care products that employ them as a modifier that results in increased sensory attributes and increased effectiveness in the deposition of actives and can also act as a thickening agent. The copolymer includes one or more repeating units derived from olefinically unsaturated anionic or anionogenic or zwitterionic comonomers, and one or more repeating units having the formula | 2017-09-14 |
20170258704 | COSMETIC COMPOSITION COMPRISING AN OIL, HYDROPHOBIC SILICA AEROGEL PARTICLES, AND A HYDROCARBON-BASED BLOCK COPOLYMER PREFERABLY OBTAINED FROM AT LEAST ONE STYRENE MONOMER - The present invention relates to a cosmetic composition for making up and/or caring for the skin and/or the lips, including, in a physiologically acceptable medium,
| 2017-09-14 |
20170258705 | ROSE-PETAL BODY WASH AND PREPARATION METHOD THEREOF - A rose-petal body wash which comprises the following raw materials by mass percentage: solvent, suspending agent, thickener, humectant, odorant, neutralizer, emollient, chelating agent, preservative, color stabilizing agent, colorant, and its preparation method which comprises the following steps: (1) clean an agitator kettle completely and clean up the rose petals in advance; (2) pump in de-ionized water and start agitation, then feed partial raw materials in turn, then heat them up to 85° C. and agitate to dissolve completely, (3) after the raw materials dissolve, cool the system down to 50° C. and add NaOH solution to adjust it to a transparent solution, then add some other raw materials, (4) cool the system to 45° C., then add the remaining raw materials and adjust to an acceptable color before discharging, (5) discharge and inspect the product, if it is acceptable, store as finished product. | 2017-09-14 |
20170258706 | LIP COMPOSITIONS CONTAINING FOOD POWDER - Disclosed herein are cosmetic lip compositions that contain dried food powders. The dried food powders are present in about 1% to about 20% and impart flavor to the lip compositions. The lip compositions can be solid (e.g., balms, lipsticks) or semi-solid (e.g, gels in tubes) and can be made using known manufacturing processes. | 2017-09-14 |
20170258707 | TOPICAL SKIN CARE FORMULATIONS COMPRISING BOTANICAL EXTRACTS - Disclosed is a topical skin composition comprising an aqueous extract from a part of | 2017-09-14 |
20170258708 | MEANS AND METHODS FOR PREVENTING AND/OR TREATING CARIES - The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to | 2017-09-14 |
20170258709 | TOPICAL SKIN FORMULATIONS - A method of treating a person's skin comprising topically applying to skin a composition that includes an effective amount of a hydrolyzed algae extract that includes an exopolysaccharide from | 2017-09-14 |
20170258710 | MONTELUKAST TRANSMUCOSAL FILM - An oral film product in which a pharmaceutically active agent is stabilized in its partially-ionized form to better facilitate oral transmucosal delivery is provided. The film includes a bioadhesive layer including a pharmaceutically active agent having a logarithmic acid dissociation constant that is less than 4.5 and which is complexed with a cationic polymer. | 2017-09-14 |
20170258711 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery - The present invention relates to fatty acid acylated amino acids (FA-Daa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-Daa's. | 2017-09-14 |
20170258712 | MICRONEEDLE DEVICE - A microneedle device includes a substrate; a microneedle projecting from the substrate and configured to be inserted into skin; and a drug coating the microneedle. An aspect ratio of a maximum width of a base of the microneedle to a height of the microneedle is equal to or greater than 2.1. | 2017-09-14 |
20170258713 | COLLAPSIBLE PATCH ANDMETHOD OF APPLICATION - A microneedle patch includes a base, at least one collapsible side wall extending from the base, and a lip disposed along the at least one collapsible sidewall and opposite the base. An adhesive is disposed along the base, and a microneedle array is affixed to the base. | 2017-09-14 |
20170258714 | NANOVECTORS FOR PENETRATING BRAIN TUMOR TISSUES TO CONDUCT GENE THERAPY - A method of selectively targeting a cell with a therapeutic agent, the method comprising: targeting a cell with a nanospear, puncturing the cell with said nanospear; releasing a therapeutic agent from said nanospear, wherein said therapeutic agent enters said cell, thereby effecting the efficacy of said cell. | 2017-09-14 |
20170258715 | COMPOSITION AND METHOD OF USE OF COLCHICINE ORAL LIQUID - Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided. | 2017-09-14 |
20170258716 | ANTI-CANCER AGENT FOR USE IN COMBINATION THERAPY OF HIGH INTENSITY FOCUSED ULTRASOUND THERAPY AND ANTI-CANCER AGENT THERAPY - The present invention provides a cancer treatment method in which side effects are inhibited. Specifically, in a combination therapy of a high intensity focused ultrasound therapy at an irradiation intensity of 320 to 700 W/cm | 2017-09-14 |
20170258717 | PHARMACEUTICAL COMPOSITION COMBINING AT LEAST TWO DISTINCT NANOPARTICLES AND A PHARMACEUTICAL COMPOUND, PREPARATION AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle. | 2017-09-14 |
20170258718 | PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the nanoparticle potentiates the pharmaceutical compound efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, its absolute surface charge value is of at least 10 mV (|10 mV|), and its Young modulus is less than 100 kPa. The invention also relates to such a composition for use for administering the pharmaceutical compound in a subject in need thereof, wherein the at least one nanoparticle and the at least one pharmaceutical compound are to be administered in the subject between more than 5 minutes and about 72 hours one from each other. | 2017-09-14 |
20170258719 | LIPOSOMAL APPARATUS AND MANUFACTURING METHODS - The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol. | 2017-09-14 |
20170258720 | PHARMACEUTICAL COMPOSITIONS, PREPARATION AND USES THEREOF - The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability. The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours. | 2017-09-14 |
20170258721 | PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other. | 2017-09-14 |
20170258722 | ENCAPSULATING LIPOSOMES - Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, and uses of liposomes encapsulating a biologically active agent to treat a subject. | 2017-09-14 |
20170258723 | ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE - [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation. | 2017-09-14 |
20170258724 | METHOD OF BORON NITRIDE NANOPARTICLE FABRICATION FOR ANTITUMOR DRUG DELIVERY - This invention relates to nanomedical technologies, namely to the fabrication of nanocarriers of drugs for antitumor chemotherapy. The technical result of the invention consists of increasing the efficiency of antitumor chemotherapy by increasing the activity of the cell absorption of nanocontainers loaded with an antitumor drug, avoiding of the nanocontainer toxicity for cells due to the use of dispersed boron nitride nanoparticles of 50-300 nm in diameter with a well-developed outer surface. The method of boron nitride nanoparticles fabrication for antitumor drug delivery to tumor cells includes synthesis of spherical boron nitride nanoparticles of 50-300 nm in diameter with a well-developed outer surface by chemical vapor deposition using ammonia reaction gas, argon transport gas and powder mixture composed of amorphous boron and oxidizing reactants. | 2017-09-14 |
20170258725 | FORMULATION COMPRISING PARTICLES - The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof. | 2017-09-14 |
20170258726 | Spray-Freeze Drying of Polyelectrolyte Nanoparticles Containing the Protein Drug - The present invention relates to a process for spray-freeze-drying (SFD) a dispersion of polyelectrolyte complex (PEC) nanoparticles loaded with a protein drug, which yields a powdered product with adequate flowability properties that may readily be processed further into solid dosage forms such as tablets or capsules. The mean particle size of PEC nanoparticles obtained after redispersion of SFD powder or pharmaceutical compositions made from said powder in water is preserved in the nanometer range (<1000 nm), and so is the protein biological activity. | 2017-09-14 |
20170258727 | METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF - Disclosed herein, are methods of preparing fetal support tissue powders. Further disclosed herein, are methods of using the fetal support tissue powder product. | 2017-09-14 |
20170258728 | CELLULOSE MICROPOWDER - The present invention relates to a cellulose powder usable for a satisfactory orally disintegrating tablet having excellent compression moldability and well-balanced tablet moldability and disintegration properties, which can obtain excellent ingestion feel without feeling roughness and dryness in the oral cavity, and more particularly to a cellulose powder with an average polymerization degree of 150 to 450, an average particle diameter of not less than 10 μm but less than 100 μm, and a primary particle ratio of 50% or more. | 2017-09-14 |
20170258729 | Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor - Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2017-09-14 |
20170258730 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2017-09-14 |
20170258731 | TABLET - A method of forming an erodible sustained release tablet comprising the steps of:—a. mixing one or more therapeutic agents, one or more disintegrant and one or more molten wax, whilst retaining the wax in molten form; b. solidifying and granulating the mixture; c. forming a tablet by compression of the granules. The invention also relates to a sustained release tablet made according to the method. | 2017-09-14 |
20170258732 | METHODS AND ARTICLES FOR DELIVERING VIABLE CELLS INTO SOLID TISSUE - Embodiments provide swallowable devices, preparations and methods for delivering viable cells (VC) into the GI tract including GI wall tissue or other tissue site. Particular embodiments provide a swallowable device such as a capsule for delivering VC into an intestinal wall or other site. The VC can be contained within a tissue-penetrating shell disposed in the capsule that protects the VC as they pass through the GI tract until they are inserted into GI tract tissue or other location. The shell desirably has shape, size and material consistency to be contained in a swallowable capsule, delivered from the capsule into solid tissue by the application of force on the shell and biodegrade within the solid tissue to release the VC into the tissue. Within the shell or other structure the VC can be maintained in a viability-sustaining gel that preserves the viability of the VC for selected time periods. | 2017-09-14 |
20170258733 | HYDROXYPROPYL STARCH VACANT CAPSULES AND A PROCESS FOR PRODUCING THEM - This present invention discloses hydroxypropyl starch vacant capsules and a process for producing them, wherein said hydroxypropyl starch vacant capsules are made of hydroxypropyl starch and water and optional light-screening agent, colorant, aromatics, and flavoring agent through the processes of raw material mixup, gelatinization, stabilization, and capsule-forming. The hydroxypropyl starch capsules disclosed in this invention have such advantages as extensive source of raw material, high safety level, disintegrating property and friability over the products prepared through existing technologies. | 2017-09-14 |
20170258734 | BACTERIALLY DERIVED INTACT MINICELLS THAT ENCOMPASS PLASMID FREE DNA AND METHODS OF USING THE SAME - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. | 2017-09-14 |
20170258735 | PEPTIDE-POLYPEPTIDE CO-ASSEMBLED NANOPARTICLES FOR DRUG DELIVERY - Provided are co-assembled nanoparticles including at least one polypeptide including a polyanion; and at least one amphiphilic peptide capable of forming a β-sheet structure, a derivative or a salt thereof, the amphiphilic peptide including at least 2 pairs of alternating hydrophobic/hydrophilic amino acid residues in which the hydrophilic amino acid residue is positively charged, and methods of preparation of the nanoparticles. Further provided are pharmaceutical compositions including the co-assembled nanoparticles and a pharmaceutically active ingredient, dissolved, entrapped, encapsulated or attached to the co-assembled nanoparticles. Further provided are therapeutic uses of the pharmaceutical compositions. | 2017-09-14 |
20170258736 | Nanoparticle-based Combinatorial Therapy - The present invention provides a nano-particle based structure or composition for a combinational cancer therapy. The structure has a doxorubicin (DOX) physically loaded on core-shell silver polymeric nanoparticles (AgN-Ps) with a ratio of 3.3-5.5% doxorubicin to 1% silver to 2-10% polymer. This structure enhances the cellular uptake of DOX in comparison to the current conventional combination therapy. The DOX-loaded nano-particles result in an improved the therapeutic efficiency of DOX, and reduced its toxicity, which cannot occur in case of adding DOX and AgNPs. | 2017-09-14 |
20170258737 | TWO-DIMENSIONAL POLYMERIC STRUCTURES AND METHOD FOR PRODUCING THEREOF - The present invention relates to polymeric structures, in the form of flat membrane-like surfaces or micro- nanostruc-tures such as capsules, characterized in that it comprises a substantially two-dimensional layer of covalently-bonded monomers of R-substituted metal or metalloid oxides. Said polymeric structures in most embodiments have a crystal architecture with a hexagonal lattice, but the nature of the covalent bonds present therein impart a bending flexibility that make the polymeric structures behave as a “soft” crystal. Methods of producing such structures, composition comprising thereof and method of using thereof are also included within the present disclosure. | 2017-09-14 |
20170258738 | Multilayer Compositions, Coated Devices And Use Thereof - The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof. In some embodiments, a structure, comprising a substrate and a multilayer film on the substrate, wherein the multilayer film comprises a release layer and one or more layer-by-layer films. In some embodiments, a structure comprising a microneedle substrate and a multilayer film coated on at least portion of the microneedle substrate, wherein the multilayer film comprises an agent for delivery. | 2017-09-14 |
20170258739 | MEDICAMENT FOR ACCELERATED WOUND HEALING - A medicament for accelerated wound healing is proposed containing derivatives of the formula (I), in which R | 2017-09-14 |
20170258740 | TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE AND THROMBOSIS - Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. | 2017-09-14 |
20170258741 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY - The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNG1E), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)—N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)—N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide. | 2017-09-14 |
20170258742 | AGENT FOR INHIBITING ODOR OF PYRAZINE DERIVATIVES - Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient. | 2017-09-14 |
20170258743 | A Process for Preparation of Bioavailable White Curcumin - A Unique Blend of Hydrogenated Curcuminoids - The present invention discloses a process for preparation of white curcumin from purified curcuminoids. The curcuminoids are obtained by solvent extraction and crystallization of dried turmeric powder. The autoclave is charged with ethyl acetate and the 95% purity curcuminoids mixture is added to and stirred for uniformity at room temperature. 5% (w/w) of 10% palladium carbon is added to the reaction mixture and allowed for hydrogenation in the presence of hydrogen gas at 2 lbps pressure and stirred continuously for 15 hours. Once the reaction is completed, the reaction mixture is filtered and washed with ethyl acetate. The ethyl acetate is distilled off and crude mass is stirred with water to obtain a solid precipitate. Finally, the solid obtained is filtered and dried to pale brown crystals of white curcumin. White curcumin is encapsulated with beta-cyclodextrin, which exhibited increased bioavailability. White curcumin also exhibited anti-oxidant and chemopreventive activities. | 2017-09-14 |
20170258744 | NOVEL TREATMENT OF PROSTATE CARCINOMA - Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer. | 2017-09-14 |
20170258745 | MIXED SALT COMPOSITIONS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS - Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D | 2017-09-14 |
20170258746 | ACETIC ACID/THYMOL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF ONYCHOMYCOSIS - A composition comprising from about 1 weight part to about 10 weight parts a saturated carboxylic acid having from 2 to about 20 carbon atoms; from about 0.1 weight parts to about 10 weight parts an antifungal compound; and from about 80 weight parts to about 99 weight parts skin-penetrating gel; wherein the saturated carboxylic acid, the antifungal compound, and the skin-penetrating gel together comprise 100 weight parts. In a particular example of the composition, the saturated carboxylic acid having from 2 to about 20 carbon atoms is acetic acid; and the antifungal compound is thymol. A method of treating onychomycosis in a patient, comprising applying the composition. The method provides a safe, effective treatment of onychomycosis. | 2017-09-14 |
20170258747 | GLUTAMINE ENRICHED NUTRITIONAL COMPOSITION FOR PRETERM INFANTS - The present invention relates to the use of nutritional compositions enriched in glutamine to improve structural and functional brain development in preterm and/or low birth weight infants. | 2017-09-14 |
20170258748 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin with reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 2017-09-14 |
20170258749 | Oseltamivir Compositions - The present invention relates to pharmaceutical composition comprising two different populations with first population comprising oseltamivir or a pharmaceutical acceptable salt thereof and one or more pharmaceutically acceptable excipients and second population comprising one or more pharmaceutically acceptable excipients. Preferably, the compositions wherein the second population does not contain oseltamivir or a pharmaceutically acceptable salt thereof. The invention also disclose new method of filing the composition into container. The inventors of the present invention surprisingly found that the composition are stable in real-time and long-term stability conditions. Further, the compositions are bioequivalent to marketed suspension formulation of Oseltamivir phosphate. | 2017-09-14 |
20170258750 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT VIRAL INFECTIONS - The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV. | 2017-09-14 |
20170258751 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES - Pharmaceutical compositions comprising Fatty Acid Fumarate Derivatives, and methods of using Fatty Acid Fumarate Derivatives and pharmaceutical compositions thereof for treating heart failure diseases, including heart failure with preserved ejection fraction (HFPEF), comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed. | 2017-09-14 |
20170258752 | SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES - Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration. | 2017-09-14 |
20170258753 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2017-09-14 |
20170258754 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2017-09-14 |
20170258755 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2017-09-14 |
20170258756 | A Method for Topically Treating Actinic Keratosis on the Scalp with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate) - The invention relates to the treatment of actinic keratosis on the scalp with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). | 2017-09-14 |
20170258757 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LOADING - There is provided a conjugate of a delivery agent containing a chemical moiety and at least one flavonoid. The flavonoid exists in a monomeric form or dimeric form before conjugation and remains in the monomeric form or dimeric form after conjugation. Preferably, the conjugate comprises two flavonoids. The delivery agent is conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. An anti-cancer agent delivery vehicle comprising an anti-cancer agent and the conjugate is also provided. | 2017-09-14 |
20170258758 | METHODS FOR TREATING BRAIN METASTASIS - The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin. | 2017-09-14 |
20170258759 | METHOD OF IMPROVING VISUAL PROCESSING, VISUAL ACUITY, OR BOTH BY ADMINISTERING COMPOSITIONS COMPRISING RRR-ALPHA-TOCOPHEROL AND CAROTENOID TO INFANTS - Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are also disclosed. Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. | 2017-09-14 |
20170258760 | TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 8 (TRPM8) ANTAGONISTS AND METHODS OF USE - The invention provides methods of treating or preventing an ocular disease or disorder in a subject, methods of treating or preventing ocular pain or discomfort comprising, administering to the subject a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a transient receptor potential melastatin 8 (TRPM8) antagonist. In certain preferred embodiments, the ocular disease or disorder is a dry eye disease. | 2017-09-14 |
20170258761 | Pharmaceutical Compositions Comprising Canagliflozin - The present invention belongs to the field of pharmaceutical industry and relates to a dry pharmaceutical composition comprising Canagliflozin, as well as to a process for preparing the same. Such dry pharmaceutical composition is useful as a medicament, especially for the normalization of plasma glucose levels. | 2017-09-14 |
20170258762 | FORMULATION COMPRISING GLYCOPYRROLATE, METHOD AND APPARATUS - A method is disclosed for making a pharmaceutical composition for pulmonary administration comprising co-jet milling glycopyrrolate and magnesium stearate, wherein the co-jet milled glycopyrrolate and magnesium stearate is then subjected to a conditioning step which includes exposure of the co-jet milled glycopyrrolate and magnesium stearate to humidity. A composition made by this method is also disclosed. | 2017-09-14 |
20170258763 | RAPID DISPERSE DOSAGE FORM - A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug. | 2017-09-14 |
20170258764 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND - The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. | 2017-09-14 |
20170258765 | Priming of Pancreatic Tumor Cells and Cancer Stem Cells to TRAIL-Induced Apoptosis - This invention relates generally to compositions and methods for treatment of pancreatic cancer. The present invention relates more particularly to use of JNK inhibition together with administration of TRAIL to selectively suppress cancer stem cells. | 2017-09-14 |
20170258766 | ANGIOTENSIN IN TREATING BRAIN CONDITIONS - The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration. | 2017-09-14 |
20170258767 | METHODS FOR THE TREATMENT OF OVERACTIVE BLADDER - Disclosed herein are methods of treating overactive bladder in a patient, the method comprising identifying a patient in need thereof; and administering to the patient a composition comprising tolterodine, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, wherein after the administration C | 2017-09-14 |
20170258768 | ONDANSETRON EXTENDED RELEASE SOLID DOSAGE FORMS FOR TREATING EITHER NAUSEA, VOMITING OR DIARRHEA SYMPTOMS - A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof. | 2017-09-14 |
20170258769 | A Method for Topically Treating Actinic Keratosis on the Trunk (except chest) and Extremities with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate) - The invention relates to the treatment of actinic keratosis on the trunk (except chest) and extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). | 2017-09-14 |
20170258770 | Method for Topically Treating Actinic Keratosis on the Full Face or 250 cm2 on the Chest with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate) - The invention relates to the treatment of actinic keratosis on the full face or 250 cm | 2017-09-14 |
20170258771 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban - The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof. | 2017-09-14 |
20170258772 | COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL AND/OR NON-STEM PROGENITOR CELL FUNCTION - Disclosed herein are novel methods and compositions useful for promoting intestinal stem cell function. The methods and compositions are particularly useful for stimulating the proliferation of and/or self-renewal of intestinal stem cells, as well as for minimizing, preventing, or ameliorating cellular damage resulting from incidental or accidental exposure to radiation (e.g., cancer radiation therapy). | 2017-09-14 |
20170258773 | SOLID FORMS OF ACETIC ACID, COMPOSITIONS, AND USES THEREOF - Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. | 2017-09-14 |
20170258774 | NOVEL OXIMES FOR REACTIVATING BUTYRYLCHOLINESTERASE - Oxime molecules for reactivating butyrylcholinesterase (BChE) and methods for protection against and therapeutic treatment of the toxic effects of organophosphorus compounds (OP) cholinesterase inhibitors such as nerve agents and/or insecticides are provided. The oxime molecules can be administered to a subject in need thereof to treat or prevent toxic effects of OPs. The oxime molecules can allow for a dual reactivation treatment paradigm by reactivating both serum BChE and inactivated CNS AChE. | 2017-09-14 |
20170258775 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS - There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of kallikrein, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of kallikrein. | 2017-09-14 |
20170258776 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects - The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds. | 2017-09-14 |
20170258777 | Selective NR2B Antagonists - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. | 2017-09-14 |
20170258778 | SOLID FORMS COMPRISING 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed. | 2017-09-14 |
20170258779 | COMBINATION THERAPY FOR BIPOLAR DISORDER - The present invention relates to a method of decreasing cholesterol or low density lipid protein in a subject in need thereof comprising: administering to said subject a pharmaceuticaly effective amount of a composition comprising dextromethorphan. | 2017-09-14 |
20170258780 | TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. | 2017-09-14 |
20170258781 | ATRIAL SPECIFIC ANTIARRHYTHMICS FOR USE IN TREATING OR PREVENTING ATRIAL FIBRILLATION - The invention relates to methods and compositions for treating or preventing atrial fibrillation. | 2017-09-14 |
20170258782 | ALKYL LINKED QUINOLINYL MODULATORS OF ROR.gamma.t - The present invention comprises compounds of Formula I. | 2017-09-14 |
20170258783 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC - A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells. | 2017-09-14 |
20170258784 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 2017-09-14 |
20170258785 | COMPOSITE NANOPARTICLES AND USES THEREOF - Provided herein are composite nanoparticles, methods of making composite nanoparticles and methods of using composite nanoparticles to treat or ameliorate various diseases, such as, for example, cancer. | 2017-09-14 |
20170258786 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE - A method for treating a disease characterized by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith, comprising administering to the mammal an effective amount of a compound having the structure of any one of Formulas I-IV described herein, or a pharmaceutically acceptable salt thereof. | 2017-09-14 |
20170258787 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF - The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient. | 2017-09-14 |
20170258788 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS - The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder. | 2017-09-14 |
20170258789 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2017-09-14 |
20170258790 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists - The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R | 2017-09-14 |
20170258791 | PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND - Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. | 2017-09-14 |
20170258792 | LIGANDS THAT TARGET PLASMODIUM SPOROZOITE BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM - The invention pertains to ligands that bind to CD81 and that inhibit or block | 2017-09-14 |
20170258793 | METHOD FOR TREATING PROSTATE CANCER - The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of CDK8 and CDK19. In some embodiments the inhibitor inhibits CDK19. In some embodiments, the inhibitor inhibits CDK8 at a Kd of lower than 200 nM and/or inhibits CDK19 at a Kd of lower than 100 nM. In some embodiments, the prostate cancer is androgen independent. In some embodiments, the prostate cancer is androgen independent due to one or more of androgen receptor gene amplification, androgen receptor gene mutation, ligand-independent transactivation of androgen receptor and activation of intracellular androgen synthesis. In some embodiments, the inhibitor inhibits increased activity of NF-κB. In some embodiments, the inhibitor does not inhibit increased basal levels of NF-κB. | 2017-09-14 |
20170258794 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR - Disclosed are compounds having the formula: | 2017-09-14 |
20170258795 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX - Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer. | 2017-09-14 |
20170258796 | Methods And Compositions To Reduce Oxidative Stress - The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro. | 2017-09-14 |
20170258797 | TREATMENTS FOR AUTOIMMUNE DISEASE - The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for Hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases. Preferably the autoimmune disease is multiple sclerosis. | 2017-09-14 |
20170258798 | INJECTION PREPARATION AND METHOD FOR PRODUCING SAME - Provided are an injection preparation which include: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent which is selected from the group consisting of ascorbic acid, an ascorbic acid derivative, and salts thereof, and the content of which is 0.0001 mass % to 0.5 mass % with respect to the total mass of the aqueous composition in terms of ascorbic acid, and an aqueous solvent of greater than or equal to 50 mass % with respect to the total mass of the aqueous composition; and a container which encloses the aqueous composition, in which the concentration of oxygen in gas within the container which encloses the aqueous composition is less than or equal to 0.2 volume %, and a method for producing the injection preparation. | 2017-09-14 |
20170258799 | CAFFEINATED GUMMIES - Described herein are gummy compositions and products. In one aspect the gummy compositions include:
| 2017-09-14 |
20170258800 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME - The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof. | 2017-09-14 |